CME/CE

Episodes 97-112 of 380

• 

  MinuteCE®

  The Next Generation of Risk Stratification in Patients With PH

  1.00 credit 4 episodes

  • 

    

    Jean M. Elwing, MD

  • 

    

    Richard N. Channick, MD

  • 

    

    Victor Moles, MD

  1.00 credit 4 episodes

• 

  RestartResume

  Don’t Wait to Escalate—Getting Aggressive in PH Management

  RestartResume

  Don’t Wait to Escalate—Getting Aggressive in PH Management

  MinuteCE®

  Don’t Wait to Escalate—Getting Aggressive in PH Management

  1.00 program credit

  • 

    

    Jean M. Elwing, MD

  1.00 program credit

• 

  RestartResume

  PH Management Into the Future: Understanding the Next Generation of Treatments and Mechanisms

  RestartResume

  PH Management Into the Future: Understanding the Next Generation of Treatments and Mechanisms

  MinuteCE®

  PH Management Into the Future: Understanding the Next Generation of Treatments and Mechanisms

  1.00 program credit

  • 

    

    Victor Moles, MD

  1.00 program credit

• 

  RestartResume

  Finding the Patient With PH Among Us: How We Optimize Treatment Based on Patient Type

  RestartResume

  Finding the Patient With PH Among Us: How We Optimize Treatment Based on Patient Type

  MinuteCE®

  Finding the Patient With PH Among Us: How We Optimize Treatment Based on Patient Type

  1.00 program credit

  • 

    

    Richard N. Channick, MD

  1.00 program credit

• 

  RestartResume

  Practical Implications of New Treatments in Clinical Practice

  RestartResume

  Practical Implications of New Treatments in Clinical Practice

  MinuteCE®

  Practical Implications of New Treatments in Clinical Practice

  1.00 program credit

  • 

    

    Jean M. Elwing, MD

  • 

    

    Richard N. Channick, MD

  • 

    

    Victor Moles, MD

  1.00 program credit

• 

  RestartResume

  Managing Myelofibrosis-Associated Anemia

  RestartResume

  Managing Myelofibrosis-Associated Anemia

  MinuteCE®

  Managing Myelofibrosis-Associated Anemia

  1.00 program credit

  • 

    

    Gabriela Hobbs, MD

  1.00 program credit

• 

  RestartResume

  Treatment Options for Ruxolitinib Intolerance or Resistance in Myelofibrosis

  RestartResume

  Treatment Options for Ruxolitinib Intolerance or Resistance in Myelofibrosis

  MinuteCE®

  Treatment Options for Ruxolitinib Intolerance or Resistance in Myelofibrosis

  1.00 program credit

  • 

    

    Gabriela Hobbs, MD

  1.00 program credit

• 

  RestartResume

  Managing Myelofibrosis-Associated Thrombocytopenia

  RestartResume

  Managing Myelofibrosis-Associated Thrombocytopenia

  MinuteCE®

  Managing Myelofibrosis-Associated Thrombocytopenia

  1.00 program credit

  • 

    

    Gabriela Hobbs, MD

  1.00 program credit

• 

  MinuteCE®

  Tailoring JAK Inhibitor Therapy in Patients With Myelofibrosis

  1.00 credit 10 episodes

  • 

    

    John Mascarenhas, MD

  • 

    

    Gabriela Hobbs, MD

  1.00 credit 10 episodes

• 

  RestartResume

  Improving Transfusion Independence With JAK Inhibitor Therapy

  RestartResume

  Improving Transfusion Independence With JAK Inhibitor Therapy

  MinuteCE®

  Improving Transfusion Independence With JAK Inhibitor Therapy

  1.00 program credit

  • 

    

    John Mascarenhas, MD

  1.00 program credit

• 

  RestartResume

  Real-World Experience With Pacritinib in the US

  RestartResume

  Real-World Experience With Pacritinib in the US

  MinuteCE®

  Real-World Experience With Pacritinib in the US

  1.00 program credit

  • 

    

    John Mascarenhas, MD

  1.00 program credit

• 

  RestartResume

  Managing Treatment-Related Toxicities With JAK Inhibitor Therapy in Myelofibrosis

  RestartResume

  Managing Treatment-Related Toxicities With JAK Inhibitor Therapy in Myelofibrosis

  MinuteCE®

  Managing Treatment-Related Toxicities With JAK Inhibitor Therapy in Myelofibrosis

  1.00 program credit

  • 

    

    John Mascarenhas, MD

  1.00 program credit

• 

  RestartResume

  How to Use Prognostic Risk Scoring and Symptom Burden Assessment to Tailor Myelofibrosis Treatment

  RestartResume

  How to Use Prognostic Risk Scoring and Symptom Burden Assessment to Tailor Myelofibrosis Treatment

  MinuteCE®

  How to Use Prognostic Risk Scoring and Symptom Burden Assessment to Tailor Myelofibrosis Treatment

  1.00 program credit

  • 

    

    Gabriela Hobbs, MD

  1.00 program credit

• 

  RestartResume

  Pacritinib for Myelofibrosis Across the Cytopenic Spectrum

  RestartResume

  Pacritinib for Myelofibrosis Across the Cytopenic Spectrum

  MinuteCE®

  Pacritinib for Myelofibrosis Across the Cytopenic Spectrum

  1.00 program credit

  • 

    

    John Mascarenhas, MD

  1.00 program credit

• 

  RestartResume

  Case Discussion: What JAK Inhibitor Should I Use in a Transfusion-Dependent Patient With MF With Platelets > 50 × 10⁹/L?

  RestartResume

  Case Discussion: What JAK Inhibitor Should I Use in a Transfusion-Dependent Patient With MF With Platelets > 50 × 10⁹/L?

  MinuteCE®

  Case Discussion: What JAK Inhibitor Should I Use in a Transfusion-Dependent Patient With MF With Platelets > 50 × 10⁹/L?

  1.00 program credit

  • 

    

    John Mascarenhas, MD

  • 

    

    Gabriela Hobbs, MD

  1.00 program credit

• 

  RestartResume

  How and When to Manage Ruxolitinib Failure

  RestartResume

  How and When to Manage Ruxolitinib Failure

  MinuteCE®

  How and When to Manage Ruxolitinib Failure

  1.00 program credit

  • 

    

    John Mascarenhas, MD

  1.00 program credit